Vaccibody As Performance
| VACCDelisted Stock | USD 2.23 0.04 1.83% |
The entity has a beta of 0.0, which indicates not very significant fluctuations relative to the market. the returns on MARKET and Vaccibody are completely uncorrelated. Vaccibody As right now has a risk of 0.0%. Please validate Vaccibody day median price and relative strength index , to decide if Vaccibody will be following its existing price patterns.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Vaccibody As has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of rather sound fundamental indicators, Vaccibody is not utilizing all of its potentials. The recent stock price tumult, may contribute to shorter-term losses for the shareholders. ...more
| Begin Period Cash Flow | 214.1 M |
Vaccibody |
Vaccibody Relative Risk vs. Return Landscape
If you would invest 223.00 in Vaccibody As on October 5, 2024 and sell it today you would earn a total of 0.00 from holding Vaccibody As or generate 0.0% return on investment over 90 days. Vaccibody As is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of stocks are less volatile than Vaccibody, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Vaccibody Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Vaccibody's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Vaccibody As, and traders can use it to determine the average amount a Vaccibody's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| VACC |
Based on monthly moving average Vaccibody is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Vaccibody by adding Vaccibody to a well-diversified portfolio.
Vaccibody Fundamentals Growth
Vaccibody Stock prices reflect investors' perceptions of the future prospects and financial health of Vaccibody, and Vaccibody fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Vaccibody Stock performance.
| Return On Equity | -0.23 | |||
| Return On Asset | -0.15 | |||
| Operating Margin | (77.18) % | |||
| Current Valuation | 32.03 M | |||
| Shares Outstanding | 38.55 M | |||
| Price To Earning | 12.63 X | |||
| Price To Book | 0.36 X | |||
| Price To Sales | 2.31 X | |||
| Revenue | 44.7 M | |||
| EBITDA | 869 K | |||
| Cash And Equivalents | 192.33 M | |||
| Cash Per Share | 5.17 X | |||
| Total Debt | 8.77 M | |||
| Debt To Equity | 0.03 % | |||
| Book Value Per Share | 5.64 X | |||
| Cash Flow From Operations | (14.43 M) | |||
| Earnings Per Share | (1.59) X | |||
| Total Asset | 270.2 M | |||
| Retained Earnings | (103.24 M) | |||
About Vaccibody Performance
By analyzing Vaccibody's fundamental ratios, stakeholders can gain valuable insights into Vaccibody's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Vaccibody has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Vaccibody has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel T cell immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancers. Vaccitech plc was founded in 2016 and is headquartered in Oxford, the United Kingdom. Vaccitech Plc operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 72 people.Things to note about Vaccibody As performance evaluation
Checking the ongoing alerts about Vaccibody for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Vaccibody As help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Vaccibody As is not yet fully synchronised with the market data | |
| Vaccibody As has a very high chance of going through financial distress in the upcoming years | |
| Vaccibody As currently holds about 192.33 M in cash with (14.43 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.17, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
- Analyzing Vaccibody's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Vaccibody's stock is overvalued or undervalued compared to its peers.
- Examining Vaccibody's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Vaccibody's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Vaccibody's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Vaccibody's stock. These opinions can provide insight into Vaccibody's potential for growth and whether the stock is currently undervalued or overvalued.
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Other Consideration for investing in Vaccibody Stock
If you are still planning to invest in Vaccibody As check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Vaccibody's history and understand the potential risks before investing.
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon |